Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1) (TOPAZ-1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03875235

Recruitment Status : Active, not recruiting

First Posted : March 14, 2019

Last Update Posted : July 13, 2022

View this study on Beta.ClinicalTrials.gov

Sponsor:

Information provided by (Responsible Party):

AstraZeneca

Results Submitted - Quality Control (QC) Review Has Not Concluded

Results information for an applicable clinical trial (ACT) is posted within 30 days of submission even if the submission has not completed the ClinicalTrials.gov Results Quality Control (QC) review process. Results information is submitted to ClinicalTrials.gov by the sponsor or investigator, and National Library of Medicine (NLM) staff assess for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.

All versions of ACT results information submissions that have not completed the QC review process are posted on ClinicalTrials.gov (since January 2020). After the QC review process is completed, the results information is posted without QC review comments and previous versions are archived.

Recruitment Status :	Active, not recruiting
Actual Primary Completion Date :	August 11, 2021
Estimated Study Completion Date :	March 31, 2025

Submission Cycle	Results Submitted to ClinicalTrials.gov	Results Returned after Quality Control Review
1	August 10, 2022	September 2, 2022 Submission with QC Comments
2	January 16, 2023	February 10, 2023 Submission with QC Comments
3	March 20, 2023 (Canceled on March 20, 2023) March 21, 2023

To Top